27. Deutscher Krebskongress
Deutsche Krebsgesellschaft e. V.
22. - 26.03.2006, Berlin
Gynecologic Cancer
Meeting Abstract
(OP337)
[Volltext]
Financal calculation of a certified breast center – is there a the benefit?
Beckmann MW, Wagner S, Lux MP, Fasching PA, Universitätsbrustzentrum Franken[Volltext]
Meeting Abstract
(OP338)
[Volltext]
Improvement of prognosis of invasive ovarian cancer since 1988, especially in patients younger than 65 years of age: results of the Munich Cancer Registry
Hölscher G, Engel J, Hölzel D[Volltext]
Meeting Abstract
(OP339)
[Volltext]
Phase II trial of Docetaxel and Carboplatinum in recurrent platinum sensitive ovarian, peritoneal and tubal cancer - final results
Strauß HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Kölbl H[Volltext]
Meeting Abstract
(OP340)
[Volltext]
A randomized multicenter Phase II study on neoadjuvant chemotherapy with Carboplatin and Docetaxel in advanced ovarian carcinomas (PRIMOVAR)
Park TW, Jänicke F, Ortmann O, Hilfrich J, Breitbach GP, Höss C, Möbus V, Dietrich K, Thomssen C, Kuhn W[Volltext]
Meeting Abstract
(OP341)
[Volltext]
Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)
Belau AK, Huober J, Heilmann V, Mueller HH, Burges A, Pfisterer J, Gropp M, Schröder W, Wimberger P, du Bois A[Volltext]
Meeting Abstract
(OP342)
[Volltext]
First-line treatment of ovarian cancer FIGO stage IIB–IV using Paclitaxel/Carboplatin (TC) vs. Paclitaxel/Carboplatin followed by Topotecan (TOP): mature results of a gynecologic cancer intergroup phase III trial of the ago ovar and gineco
Jackisch C, Jackisch C, Pujade-Lauraine E, Olbricht S, Moebus V, Quaas J, Schade-Brittinger C, Richter B, Schroeder W, Lueck HJ, Pfisterer J[Volltext]
Meeting Abstract
(OP343)
[Volltext]
Prognostic significance of antibodies to HPV-16 – L1 Virus Like Partikels (VLP) in the sera of patients with invasive cervical cancer
Ackermann S, Mehlhorn G, Fasching PA, Skiba D, Beckmann MW[Volltext]
Meeting Abstract
(OP344)
[Volltext]
Expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with disease outcome
Gabriel B, zur Hausen A, Stickeler E, Dietz C, Gitsch G, Fischer DC, Bouda J, Tempfer C, Hasenburg A[Volltext]
Meeting Abstract
(OP345)
[Volltext]
Tspan-1 is strongly expressed by ovarian cancer cells
Deißler H, Scholz CJ, Sauer G, Koppold B, Kurzeder C, Kreienberg R, Deissler H[Volltext]
Meeting Abstract
(OP346)
[Volltext]
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, Diamandis EP, Schmitt M[Volltext]
Meeting Abstract
(OP347)
[Volltext]
Frequently Altered Expression of Wnt Antagonists DKK Family in Ovarian Cancer
An H, Schröter C, Bieker M, Rose F, Gross M, Niederacher D, Engenhart-Cabillic R, An H[Volltext]
Meeting Abstract
(PO348)
[Volltext]
Finaly analyzes of biweekly schedule of pegylated liposomal doxorubicin (PLD) in 64 heavily pretreated patients with relapsed ovarian cancer (ROC)
Sehouli J, Oskay-Oezcelik G, Kuehne J, Huindenburg H, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W[Volltext]
Meeting Abstract
(PO349)
[Volltext]
Combination therapy with pegliposomal doxorubicin and carboplatin in malignant gynecologic tumours. A prospective multicenter phase-II trial of the AGO-OVAR and the AGO Kommission Uterus
Harter P, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Staehle A, Koelbl H, du Bois A[Volltext]
Meeting Abstract
(PO350)
[Volltext]
The Human Endogenous Retroviral gene Syncytin is induced in endometrial Hyperplasia by Tamoxifen via the Estrogen Receptor Pathway
Strick R, Ackermann S, Beckmann MW, Strissel PL[Volltext]
Meeting Abstract
(PO351)
[Volltext]
Phase II-Studie mit wöchentlich Docetaxel in Patientinnen mit fortgeschrittenem Endometriumkarzinom, AGO Uterus-4
Günthert A, Ackermann S, Kiesel L, Steiner E, Schröder W, Camara O, Mallmann P, Emons G[Volltext]
Meeting Abstract
(PO352)
[Volltext]
Caelyx 20 mg/m2 q2wks in platinum-refractory or early recurrent ovarian or peritoneal cancer - results from a phase II study
Persing M, Beau U, Kendzierski N, Karbe I, Strauss HG, Thomssen C[Volltext]
Meeting Abstract
(PO353)
[Volltext]
Expression of glycodelin in human ovarian cancer: immunohistochemistry and possible function
Jeschke U, Kunert-Keil C, Stahn R, Scholz C, Schumacher L, Janni W, Mylonas I, Schröder E, Kuhn C, Mayr D, Briese V, Friese K[Volltext]
Meeting Abstract
(PO354)
[Volltext]
Clinical relevance of selected biochemical parameter within amniotic fluid as markers of the disordered pregnancy and under special consideration of Zytokines and Tumormarkers
Albrecht S, Köhler S, Büttner R, Zimmermann T, Kamin G, Albrecht S, Distler W[Volltext]
Meeting Abstract
(PO355)
[Volltext]
Expression of inhibin/activin subunits (alpha, betaA and betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers
Worbs S, Shabani N, Mayr D, Dian D, Kuhn C, Jeschke U, Friese K, Mylonas I[Volltext]
Meeting Abstract
(PO356)
[Volltext]
A multicenter NOGGO-feasibility study of neoadjuvant concomitant radio-chemotherapy with curative intention in locally advanced cervical carcinoma
Köhler G, Belau A, Nehmzow M, Bartz K, Breitsprecher R[Volltext]
Meeting Abstract
(PO357)
[Volltext]
Polymorphism of IL-1 α, IL-1 β and IL-10 in patients with advanced ovarian cancer
Braicu EI, Pirvulescu C, Mustea A, Könsgen D, Sehouli J, Lichtenegger W[Volltext]
Meeting Abstract
(PO358)
[Volltext]
Prognostic Role of Expression of IL-1 a, IL-1 b, IL-1 Ra and IL-10 in Advanced Epithelial Ovarian Cancer (OC)
Pirvulescu C, Braicu EI, Mustea A, Könsgen D, Sehouli J[Volltext]
Meeting Abstract
(PO359)
[Volltext]
Prognostic impact of micrometasases in pelvic lymph nodes in patients with carcinoma of the cervix uteri
Horn LC, Peter D, Hentschel B, Bilek K[Volltext]
Meeting Abstract
(PO360)
[Volltext]
Prognostic significance of inhibin/activin subunits (alpha, betaA and betaB) in human endometrial carcinoma: an immunohistochemical analysis of 294 cases
Mylonas I, Worbs S, Shabani N, Darius D, Mayr D, Kuhn C, Schulze S, Kunze S, Sommer H, Jeschke U, Friese K[Volltext]
Meeting Abstract
(PO361)
[Volltext]
Localisation and prediction of lymph node metastases in ovarian cancer
Harter P, Gnauert K, Neugebauer B, Hils R, Buhrmann C, Traut A, Fisseler-Eckhoff A, du Bois A[Volltext]
Meeting Abstract
(PO362)
[Volltext]
Implementation of an interdisciplinary Online Tumor Conference as a new tool in the management of gynaecological cancers.
Chekerov R, Sehouli J, Schönerstedt-Zastrau K, Chekerov R, Böhmer D, Denkert C, Wieding A, Heinrich G, Ruhnke M, Lorsbach M, Lichtenegger W[Volltext]
Meeting Abstract
(PO363)
[Volltext]
HPV- infection in HIV-infected women as a tumor marker of recurrent cervical dyplasia
Gingelmaier A, Grubert T, Kästner R, Mylonas I, Weissenbacher T, Barthell E, Bergauer F, Friese K[Volltext]
Meeting Abstract
(PO364)
[Volltext]
Expression of HPV, steroid receptors and inhibin/activin subunits in diverse parts of endometroid adenocarcinoma with squamous differentiation
Gutsche S, Mylonas I, Shabani N, Kuhn C, Kunze S, Jeschke U, Friese K[Volltext]
Meeting Abstract
(PO365)
[Volltext]
Proliferation and Cell-Cell Fusion of Endometrial Carcinoma are induced by the Human Endogenous Retroviral Syncytin and regulated by TGF-β
Strick R, Ackermann S, Langbein M, Beckmann MW, Strissel PL[Volltext]
Meeting Abstract
(PO366)
[Volltext]
The results of a prospective study from expression of VEGF, VEGF-C, VEGF-D in patients with ovarian cancer
Sentschuk- Schmidt N, Mustea A, Koensgen D, Sehouli J, Lichtenegger W[Volltext]
Meeting Abstract
(PO367)
[Volltext]
Nutritional status of outpatients with gynaecologic cancer
Hollatz E, Kuhberg M, Loschen K, Sehouli J, Lichtenegger W[Volltext]
Meeting Abstract
(PE368)
[Volltext]
Management and course of histological verified cervical carcinoma in situ during pregnancy
Ackermann S, Mehlhorn G, Reissmann C, Beckmann MW[Volltext]
Meeting Abstract
(PE369)
[Volltext]
Feasibility and outcome of primary and adjuvant cervical cancer patients treatment with simultaneous Radio-Chemotherapy in an outpatient setting
Buhrmann C, Hils R, Prott FJ, Gnauert K, Traut A, du Bois A[Volltext]
Meeting Abstract
(PE370)
[Volltext]
Advanced Ovarian Cancer (OC) with Mainly Extraovarian Manifestation in a 22-Year Old Pregnant Patient: Diagnostic Issues
Belau AK, Bartz K, Hinken B, Schwesinger G, Koehler G[Volltext]
Meeting Abstract
(PE371)
[Volltext]
Prognostic impact of hemoglobin levels before and throughout a carboplatin/taxane-based chemotherapy on patients with primary epithelial ovarian cancer
Eichbaum M, Weiss L, Bruckner T, Gebauer G, Schneeweiss A, Fersis N, Sohn C[Volltext]
Meeting Abstract
(PE372)
[Volltext]
Ovarian Cancer Treatment Reality in Northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as the cause for inferior survival. A Retrospective Study of 139 Patients Receiving Chemotherapy and Palliative Care in an Oncology Group Practice.
Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H[Volltext]
Meeting Abstract
(PE373)
[Volltext]
Detection ofGene Amplification in Dysplastic Lesion of the Vulva and Cervix by FISH Analysis of Chromosome 3 - preliminary results
Gebauer G, Schleibaum J, Aulmann S, Sohn C, Sinn HP[Volltext]
Meeting Abstract
(PE374)
[Volltext]
Radiochemosensitivity testing (TRCA) in Gynecological Cancers
Albrecht S, Franz R, Zimmermann T, Doerfler A, Gatzweiler A, Distler W[Volltext]
Meeting Abstract
(PE375)
[Volltext]
Long term results of postoperative radiotherapy in carcinoma of the uterine cervix
Schüller P, Funk WK, Willich N[Volltext]
